On September 9, 2021 Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, reported that Feng Tian, Ph.D., President and Chief Executive Officer of Ambrx, will participate in a virtual panel discussion at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place September 13-15, 2021 (Press release, Ambrx, SEP 9, 2021, View Source [SID1234587557]). The discussion will be led by Michael King, Managing Director and Senior Biotechnology Analyst at H.C. Wainwright.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Discussion Topic: Engineered Cytokines: The Next Big Wave in Immuno-Oncology.
Date and Time: Tuesday, September 14, 2021, at 1:30 pm EDT, 10:30 am PDT.

Individuals interested in listening to the panel discussion may do so using the webcast link under "Latest Events" in the Investors section of the company’s website at: www.ambrx.com.